Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study

American Journal of Human Genetics

Volumn 72, Issue 1, 2003, Pages 13-22

  Chen, Qi ^a   Reis, Steven E ^b   Kammerer, Candace M ^a   McNamara, Dennis M ^b   Holubkov, Richard ^c   Sharaf, Barry L ^d   Sopko, George ^e   Pauly, Daniel F ^f   Merz, C Noel Bairey ^g   Kamboh, M Ilyas ^a,h  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; CYSTEINE; GLUTAMINE; LEUCINE; METHIONINE; SERINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE MARKER; DISEASE SEVERITY; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT CODING; PRIORITY JOURNAL; RISK FACTOR;

PIERINAE;

EID: 0037219558     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/345312     Document Type: Article

References (57)

1. Al Suwaidi J, Higano ST, Hamasaki S, Holmes DR, Lerman A (2001) Association between obesity and coronary atherosclerosis and vascular remodeling. Am J Cardiol 88:1300-1303
2. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18:1617-1624
3. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517
4. Aynacioglu AS, Kepekci Y (2000) The human paraoxonase Gln-Argl92 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 74:33-37
5. Bittner V, Olson M, Kelsey SF, Rogers WJ, Merz CN, Armstrong K, Reis SE, Boyette A, Sopko G (2000) Effect of coronary angiography on use of lipid-lowering agents in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am J Cardiol 85:1083-1088
6. Blatter MC, James RW, Messmer S, Barja F, Pometta D (1993) Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: Identity of K-45 with paraoxonase. Eur J Biochem 211: 871-879
7. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442
8. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480
9. Fried LP, Pearson TA (1987) The association of risk factors with arteriographically defined coronary artery disease: What is the appropriate control group? Am J Epidemiol 125:844-853
10. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
11. Gardemann A, Philipp M, Heß K, Katz N, Tillmanns H, Haberbosch W (2000) The paraoxonase Leu-Met54 and GinArg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152:421-431
12. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66
13. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA (1989) High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 79:8-15
14. Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: Support for the oxidative damage hypothesis? Am J Hum Genet 62:20-24
15. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3: 73-76
16. Ihaka G (1996) A language for data analysis and graphics. J Comput Graph Stat 5:299-314
17. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435-442
18. 55 genotype. Arterioscler Thromb Vasc Biol 20:2441-2447
19. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA (1994) Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33:832-839
20. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259-264
21. Lipid Research Clinics Program (1974) The Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. National Institutes of Health, Bethesda, MD
22. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457
23. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEB8 Lett 423:57-60
24. Mackness MI, Arrol S, Abbott C, Durrington PN (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135
25. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEB8 Lett 286:152-154
26. Mackness MI, Durrington PN (1995) HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115:243-253
27. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN (1997) Presence of paraoxonase in human interstitial fluid. FEBS Lett 416:377-380
28. Martin GM, Austad SN, Johnson TE (1996) Genetic analysis of ageing: Role of oxidative damage and environmental stresses. Nat Genet 13:25-34
29. Merz CN, Kelsey SF, Pepine CJ, Reichek N, Reis SE, Rogers WJ, Sharaf BL, Sopko G (1999) The Women's Ischemia Syndrome Evaluation (WISE) study: Protocol design, methodology and feasibility, report. J Am Coll Cardiol 33:1453-1461
30. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM (1996) The yin and yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16:831-842
31. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res 41:1495-1508
32. Newman SC (2001) Biostatistical Methods in Epidemiology. John Wiley & Sons, New York
33. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276: 44444-44449
34. 192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257-2260
35. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M (1998) The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18:1611-1616
36. Papas AM (1996) Determinants of antioxidant status in humans. Lipids Suppl 31:S77-S82
37. Pearson TA, Derby CA (1991) Invited commentary: Should arteriographic case-control studies be used to identify causes of atherosclerotic coronary artery disease? Am J Epidemiol 134:123-128
38. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507
39. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542-547
40. Reed D, Yano K (1991) Predictors of arteriographically defined coronary stenosis in the Honolulu Heart Program: Comparisons of cohort and arteriography series analyses. Am J Epidemiol 134:111-122
41. Richter RJ, Furlong CE (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-753
42. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
43. Sanghera DK, Aston CE, Saha N, Kamboh MI (1998a) DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62:36-44
44. Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073
45. Sanghera DK, Saha N, Kamboh MI (1998b) The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 136:217-223
46. Sentí M, Tomás M, Marrugat J, Elosua R (2001) Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol 21:415-420
47. Sharaf BL, Williams DO, Miele NJ, McMahon RP, Stone PH, Bjerregaard P, Davies R, Goldberg AD, Parks M, Pepine CJ, Sopko G, Conti CR (1997) A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: Results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory. J Am Coll Cardiol 29:78-84
48. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ (1996) Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 97:1630-1639
49. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organo-phosphate toxicity and atherosclerosis. Nature 394:284-287
50. Steinberg D, Carew TE, Fielding C, Fogelman AM, Mahley RW, Sniderman AD, Zilversmit DB (1989) Lipoproteins and the pathogenesis of atherosclerosis. Circulation 80:719-723
51. Topic E, Timundic AM, Ttefanovic M, Demarin V, Vukovic V, Lovrencic-Huzjan A, Zuntar I (2001) Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin Chem Lab Med 39:346-350
52. Tsai HJ, Sun G, Weeks DE, Kaushal R, Wolujewicz M, McGarvey ST, Tufa J, Viali S, Deka R (2001) Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: No evidence of association. Am J Hum Genet 69:1236-1244
53. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M (1995) Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882-2891
54. Witztum JL, Steinberg D (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792
55. Xie X, Ott J (1993) Testing linkage disequilibrium between a disease gene and marker loci. Am J Hum Genet Suppl 53:1107
56. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17: 3565-3569
57. Zhao JH, Curtis D, Sham PC (2000) Model-free analysis and permutation tests for allelic associations. Hum Hered 50:133-139